Mal-peg5-nhs ester

Catalog No. :
ACBXQW816
CAS No. :
1807537-42-3
Molecular Formula :
C21H30N2O11
Molecular Weight :
486.47

IUPAC Name:2,5-dioxopyrrolidin-1-yl 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,6,9,12,15-pentaoxaoctadecan-18-oate

Mal-peg5-nhs ester structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$85.00Login to see priceIn stockInquiry
250mg95%$188.00Login to see priceIn stockInquiry
1g95%$522.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameMal-peg5-nhs ester
IUPAC Name2,5-dioxopyrrolidin-1-yl 1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3,6,9,12,15-pentaoxaoctadecan-18-oate
MDL No.MFCD26127781
Molecular FormulaC21H30N2O11
Molecular Weight486.47
SMILESO=C(ON1C(CCC1=O)=O)CCOCCOCCOCCOCCOCCN2C(C=CC2=O)=O
InChI KeyPDFXZGGPCFZXJU-UHFFFAOYSA-N
SynonymMal-PEG5-NHS ester;Mal-PEG5-NHS;4,7,10,13,16-Pentaoxaoctadecanoic acid, 18-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-, 2,5-dioxo-1-pyrrolidinyl ester;Mal-PEG5-CH2CH2COONHS
CAS No.1807537-42-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACBXQW816 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBXQW816 route product structure diagram
    ACBXQW8161807537-42-3 In Stock
Inquiry

2. ACBXQW816 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBXQW816 route product structure diagram
    ACBXQW8161807537-42-3 In Stock
Inquiry

Comments (0)